MLTX
Price:
$46.4
Market Cap:
$2.92B
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.[Read more]
Industry
Biotechnology
IPO Date
2020-10-20
Stock Exchange
NASDAQ
Ticker
MLTX
According to MoonLake Immunotherapeutics’s latest financial reports and current stock price. The company's current PE Ratio is -53.33. This represents a change of -25.22% compared to the average of -71.32 of the last 4 quarters.
The mean historical PE Ratio of MoonLake Immunotherapeutics over the last ten years is -485.43. The current -53.33 PE Ratio has changed 998.61% with respect to the historical average. Over the past ten years (40 quarters), MLTX's PE Ratio was at its highest in in the December 2020 quarter at 0. The PE Ratio was at its lowest in in the March 2021 quarter at -494.85.
Average
-485.43
Median
-43.58
Minimum
-1853.11
Maximum
-1.45
Discovering the peaks and valleys of MoonLake Immunotherapeutics PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.62%
Maximum Annual PE Ratio = -1.45
Minimum Annual Increase = -99.92%
Minimum Annual PE Ratio = -1853.11
Year | PE Ratio | Change |
---|---|---|
2023 | -82.39 | 1.62% |
2022 | -4.78 | 230.62% |
2021 | -1.45 | -99.92% |
The current PE Ratio of MoonLake Immunotherapeutics (MLTX) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-29.54
5-year avg
-485.43
10-year avg
-485.43
MoonLake Immunotherapeutics’s PE Ratio is less than Terns Pharmaceuticals, Inc. (0), less than Day One Biopharmaceuticals, Inc. (-5.51), less than Acumen Pharmaceuticals, Inc. (-17.12), less than Amylyx Pharmaceuticals, Inc. (-2.73), less than Aerovate Therapeutics, Inc. (-2.34), less than Enliven Therapeutics, Inc. (-0.89), less than Structure Therapeutics Inc. (-16.05), less than Compass Therapeutics, Inc. (-19.52), less than Ventyx Biosciences, Inc. (-5.11), less than Nuvalent, Inc. (-0.89), less than Cerevel Therapeutics Holdings, Inc. (-33.32), less than Travere Therapeutics, Inc. (-17.73), less than Arcellx, Inc. (-4.01), greater than Akero Therapeutics, Inc. (-85.84), less than 89bio, Inc. (-10.86), less than Pliant Therapeutics, Inc. (-5.31), less than null (-4.72),
Company | PE Ratio | Market cap |
---|---|---|
0 | $599.50M | |
-5.51 | $1.49B | |
-17.12 | $177.24M | |
-2.73 | $388.07M | |
-2.34 | $78.52M | |
-0.89 | $1.31B | |
-16.05 | $2.27B | |
-19.52 | $233.90M | |
-5.11 | $151.94M | |
-0.89 | $6.25B | |
-33.32 | $8.19B | |
-17.73 | $1.41B | |
-4.01 | $4.65B | |
-85.84 | $2.23B | |
-10.86 | $983.90M | |
-5.31 | $881.01M | |
-4.72 | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like MoonLake Immunotherapeutics using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like MoonLake Immunotherapeutics or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is MoonLake Immunotherapeutics's PE Ratio?
How is the PE Ratio calculated for MoonLake Immunotherapeutics (MLTX)?
What is the highest PE Ratio for MoonLake Immunotherapeutics (MLTX)?
What is the 3-year average PE Ratio for MoonLake Immunotherapeutics (MLTX)?
What is the 5-year average PE Ratio for MoonLake Immunotherapeutics (MLTX)?
How does the current PE Ratio for MoonLake Immunotherapeutics (MLTX) compare to its historical average?